Integra LifeSciences (IART) - רווח נקי למניה (EPS TTM)
Regulatory challenges have temporarily weakened the pricing power of Integra LifeSciences (IART), as clearly demonstrated by the TTM EPS history. However, 0.16 shows the current value of the metric, confirming the resilience of this neurosurgery leader with unique tissue regeneration patents. Confidence in quality is further bolstered by the implementation of sustainable production standards and the optimization of raw material supply chains to minimize industrial waste.
IART (Integra LifeSciences Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Net income per share over 12 months measures the equity resilience of the business, reflecting the actual yield of each security after adjusting the total financial result for the volume of issuance. Amid geopolitical supply disruptions and patent risks for Integra LifeSciences (IART), the current EPS TTM level allows for an assessment of the company's ability to generate profit despite logistical barriers, thereby determining the asset's fundamental value.
